C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter A—GeneralPart 10—Administrative Practices and ProceduresSubpart B—General Administrative Procedures

21 C.F.R. § 10.25 (2026)

Initiation of administrative proceedings

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1977–2026 71citing cases
At a glance

Courts have cited this section in 71 opinions since 1977, 14 of them in the last five years. The most litigated part is subsection (a) (1 case).

An administrative proceeding may be initiated in the following three ways:

(a) An interested person may petition the Commissioner to issue, amend, or revoke a regulation or order, or to take or refrain from taking any other form of administrative action. A petition must be either:

(1) In the form specified in other applicable FDA regulations, e.g., the form for a color additive petition in § 71.1, for a food additive petition in § 171.1 or § 571.1, for a new drug application in § 314.50, for a request to establish or amend an import tolerance in § 510.205, for a new animal drug application in § 514.1, or

(2) in the form for a citizen petition in § 10.30.

(b) The Commissioner may initiate a proceeding to issue, amend, or revoke a regulation or order or take or refrain from taking any other form of administrative action. FDA has primary jurisdiction to make the initial determination on issues within its statutory mandate, and will request a court to dismiss, or to hold in abeyance its determination of or refer to the agency for administrative determination, any issue which has not previously been determined by the agency or which, if it has previously been determined, the agency concluded should be reconsidered and subject to a new administrative determination. The Commissioner may utilize any of the procedures established in this part in reviewing and making a determination on any matter initiated under this paragraph.

(c) The Commissioner will institute a proceeding to determine whether to issue, amend, or revoke a regulation or order, or take or refrain from taking any other form of administrative action whenever any court, on its own initiative, holds in abeyance or refers any matter to the agency for an administrative determination and the Commissioner concludes that an administrative determination is feasible within agency priorities and resources.

[44 FR 22323, Apr. 13, 1979, as amended at 54 FR 9034, Mar. 3, 1989; 86 FR 52409, Sept. 21, 2021]
The 20 cases that cite 21 C.F.R. § 10.25 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENAss'n of Am. Physicians & Surgeons v. Food & Drug Admin., 539 F. Supp. 2d 4 (D.D.C. 2008).
cites § 10.25 3×cited by 22 cases
Where it cites § 10.25
“Plaintiffs may file a citizen petition under 21 C.F.R. §§ 10.25 , 10.30. The Court therefore concludes that plaintiffs’ alleged informational injuries are inadequate to support constitutional standing here.”
2
GREENCerveny v. Aventis, Inc., 855 F.3d 1091 (10th Cir. 2017).
cites § 10.25 1×cited by 53 cases
Where it cites § 10.25
“’’ 21 C.F.R. § 10.25 (a). Accordingly, any citizen may ask the FDA to change or strengthen drug labels.”
The case’s holding
The rejection of a citizen petition containing arguments identical to a proposed label change constitutes clear evidence that the FDA would not have approved the desired warning.
Later courts cite it for
“the movant must submit an affidavit (1) identifying the probable facts that are unavailable, (2) stating why these facts cannot be presented without additional time, (3) identifying past steps to obtain evidence of these facts, and (4) stating how additional time would allow for rebuttal of the adversary's argument for summary judgment.” · 17 citing courts
cites § 10.25 2×cited by 103 cases
Where it cites § 10.25
“at 160 ; see 21 C.F.R. §§ 10.25 , 10.30. Although it is unclear whether the letter in IMS Ltd.”
The case’s holding
An informal regulatory letter from the FDA is not final agency action if it does not commit the agency to enforcement action.
Later courts cite it for
“the type of informal letter issued by the fda . . . does not constitute the kind of formal or final agency action the supreme court had in mind.” · 4 citing courts
4
GREENAlpharma Inc v. Leavitt, Michael, 460 F.3d 1 (D.C. Cir. 2006).
cites § 10.25 1×cited by 186 cases
The case’s holding
An agency must provide a reasoned explanation for its actions, and post hoc rationalizations offered for the first time in litigation are insufficient for review.
Later courts cite it for
“needless to say, if it is appropriate for a court to remand for further explanation, it is incumbent upon the court to consider that explanation when it arrives.” · 6 citing courts
5
GREENIn re Lipitor Antitrust Litig., 336 F. Supp. 3d 395 (D.N.J. 2018).
cites § 10.25 1×cited by 38 cases
Where it cites § 10.25
“" 21 C.F.R. §§ 10.25 , 10.30. Here, Defendants make a similar "but for" argument as discussed above in Wellbutrin and contend that before addressing the merits of the sham citizen petition claim, Plaintiffs must first prove that the challenged patent was invalid, because if it…”
The case’s holding
State antitrust and consumer protection claims are not preempted by federal patent law when the claims require proof of elements beyond a patent cause of action.
Later courts cite it for
“accept all well-pleaded factual allegations . . . as true and draw all reasonable inferences in favor of the nonmoving party.” · 4 citing courts
6
GREENRobert Perez v. Nidek Co., 711 F.3d 1109 (9th Cir. 2013).
cites § 10.25 1×cited by 111 cases
Where it cites § 10.25
“The FDA is responsible for investigating potential violations of the FDCA, and the Act provides the agency with a range of enforcement mechanisms, such as injunction proceedings, civil and criminal penalties, and seizure.”
The case’s holding
State law fraud by omission claims are preempted when they rest solely on the non-disclosure of facts tied to the scope of a medical device's premarket approval.
Later courts cite it for
“rests within the enforcement authority of the fda, not this court.” · 4 citing courts
cites § 10.25 1×cited by 30 cases
Where it cites § 10.25
“249 , 260 (2012) (quoting 21 C.F.R. §§ 10.25 , 10.30). . Federal jurisdiction in this case is provided by the Class Action Fairness Act of 2005.”
The case’s holding
An antitrust plaintiff must plead that a defendant's anticompetitive act was a material and but-for cause of the injury, though it need not be the sole cause.
Later courts cite it for
“to survive a motion to dismiss, a complaint must contain sufficient factual matter, accepted as true, to 'state a claim to relief that is plausible on its face.” · 8 citing courts
8
GREENBracco Diagnostics, Inc. v. Shalala, 963 F. Supp. 20 (D.D.C. 1997).
cites § 10.25 2×cited by 47 cases
Where it cites § 10.25
“See 21 C.F.R. § 10.25 . Braceo was the first to file its petition on December 27,1996.”
The case’s holding
An agency acts arbitrarily and capriciously when it treats functionally indistinguishable products differently without providing a legitimate reason for the disparate treatment.
Later courts cite it for
“while the injury to plaintiffs is admittedly economic, there is no adequate compensatory or other corrective relief that can be provided at a later date, tipping the balance in favor of injunctive relief.” · 5 citing courts
9
GREENPhotoMedex, Inc. v. Irwin, 601 F.3d 919 (9th Cir. 2010).
cites § 10.25 1×cited by 57 cases
Where it cites § 10.25
“21 C.F.R. §§ 10.25 (a), 10.30. Section 337(a) of the FDCA bars private enforcement of the statute, stating that “all such proceedings for the enforcement, or to restrain violations, of this[Act] shall be by and in the name of the United States.”
The case’s holding
A private Lanham Act action is barred if the claim requires litigation of an underlying Food, Drug, and Cosmetic Act violation that the FDA has not concluded occurred.
Later courts cite it for
“because the fdca forbids private rights of action under that statute, a private action brought under the lanham act may not be pursued when, as here, the claim would require litigation of the alleged underlying fdca violation in a circumstance where the fda has not itself concluded that there was such a violation.” · 11 citing courts
10
GREENReckis v. Johnson & Johnson, 28 N.E.3d 445 (Mass. 2015).
cites § 10.25 1×cited by 41 cases
Where it cites § 10.25
“” 21 C.F.R. § 10.25 (a)(2) (1989). See In re Prograf Antitrust Litig.”
The case’s holding
Expert testimony is required to establish medical causation in a failure-to-warn claim.
Later courts cite it for
“even assuming for sake of argument that we could predict the fda would have rejected a citizen petition proposal to add only this warning, that would not answer whether the fda would have rejected the warning had it been sought by the defendants themselves” · 2 citing courts
cites § 10.25 1×cited by 12 cases
Where it cites § 10.25
“at 4-5; 21 C.F.R. § 10.25 (a) (“An interested person may petition the Commissioner [of the FDA] to issue, amend, or revoke a regulation or order, or to take or refrain from taking any other form of administrative action .”
12
GREENOtsuka Pharm. Co. v. Burwell, 302 F. Supp. 3d 375 (D.C. Cir. 2016).
cites § 10.25 1×cited by 9 cases
Where it cites § 10.25
“On February 29, 2016, Defendants filed a notice informing the Court that the three-year exclusivity period afforded to Abilify Maintena under romanette iii had expired the previous day (on February 28, 2016). ( See Notice, ECF No. 36.”
Later courts cite it for
“in some abstract sense, ambiguous, but rather whether, read in context and using the traditional tools of statutory construction,' the terms unambiguously mean what the party claiming victory at step one says they mean.” · 3 citing courts
13
GREENStevens v. Boston Sci. Corp., 152 F. Supp. 3d 527 (S.D. W. Va. 2016).
cites § 10.25 3×cited by 2 cases
Where it cites § 10.25
“See 21 C.F.R. §§ 10.25 , 10.30. In fact, the FDA, through its regulations, has.”
14
GREENIn re Flonase Antitrust Litig., 284 F.R.D. 207 (E.D. Pa. 2012).
cites § 10.25 1×cited by 21 cases
Where it cites § 10.25
“21 C.F.R. §§ 10.25 (a), 10.30. Until 2007, the FDA was required to consider and respond to every citizen petition.”
Later courts cite it for
“resolving the allegations surrounding defendant's alleged conduct in delaying generic entry will resolve issues that are 'central to the validity of each one of the claims in one stroke.” · 2 citing courts
15
GREENFarm-To-Consum. Legal Def. Fund v. Sebelius, 734 F. Supp. 2d 668 (N.D. Iowa 2010).
cites § 10.25 9×cited by 1 case
Where it cites § 10.25
“They contend that the plaintiffs have made no attempt to avail themselves of, much less exhaust, administrative remedies available to them, consisting of a citizen’s petition with the FDA pursuant to 21 C.F.R. §§ 10.25 and 10.30. The defendants contend that, pursuant to 21 C.”
16
GREENStauber v. Shalala, 895 F. Supp. 1178 (W.D. Wis. 1995).
cites § 10.25 3×cited by 7 cases
Where it cites § 10.25
“21 C.F.R. §§ 10.25 and 10.45. Defendants do not argue that the agency’s decision to approve Posilac was not final; rather, it appears that they consider the decision on labeling outside the scope of the agency’s decision to approve Posilac, at least for exhaustion purposes.”
17
GREENViropharma Inc. v. Hamburg, 898 F. Supp. 2d 1 (D.D.C. 2012).
cites § 10.25 1×cited by 20 cases
Where it cites § 10.25
“2006); 21 C.F.R. §§ 10.25 (a), 10.30(e). 12 . After ViroPharma’s sNDA was approved on December 14, 2011, ViroPharma filed another supplement to its Citizen Petition requesting three years of exclusivity pursuant to 21 U.”
The case’s holding
Under deferential review, an agency interpretation that is a reasonable policy choice is upheld, and a drug manufacturer must show that the interpretation is something other than reasonable to prevail.
Later courts cite it for
“anything other than a reasonable policy choice for the fda to have made.” · 2 citing courts
18
GREENSchering Corp. v. Food & Drug Admin., 51 F.3d 390 (3d Cir. 1995).
cites § 10.25 1×cited by 44 cases
Where it cites § 10.25
“On December 4, 1989, Schering filed a Citizen Petition with the FDA, pursuant to 21 C.F.R. § 10.25 (1990), seeking inter alia a declaration that section 355(j)(7)(B) set forth the exclusive means for determining bioequivalenee in terms of the rate and extent of drug absorption…”
The case’s holding
A potential loss of monopoly profits resulting from the approval of a generic substitute constitutes a sufficient injury in fact to establish Article III standing.
Later courts cite it for
“judgments as to what is required to ascertain the safety and efficacy of drugs falls squarely within the ambit of the fda's expertise and merit deference from us.” · 4 citing courts
19
GREENDuggan v. Medtronic, Inc., 840 F. Supp. 2d 466 (D. Mass. 2012).
cites § 10.25 1×cited by 16 cases
Where it cites § 10.25
“See 21 C.F.R. §§ 10.25 (a), 10.30 (permitting interested persons to petition the agency to take administrative action).”
Later courts cite it for
“claims involving a device that received premarket approval satisfy the first condition of the test for preemption while claims involving a device that received 510(k) approval do not.” · 2 citing courts
20
GREENGisvold v. Merck & Co., 62 F. Supp. 3d 1198 (S.D. Cal. 2014).
cites § 10.25 2×cited by 5 cases
Where it cites § 10.25
“21 C.F.R. § 10.25 . Plaintiffs reliance on Corra and Lombardo is unpersuasive because those courts did not consider the effect of 21 C.”

Show all 71 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
197720012026

One bar per year. Tallest: 5 cases in 2007. 2026 is a partial year. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D.D.C.23D.C. Cir.89th Cir.5S.D. Cal.3E.D. Pa.310th Cir.22d Cir.2D. Mass.2

The 8 courts with the most citing cases, of 28 courts in all.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com